So according to you Novartis will walk because the trial failed to meet primary endpoint? Your logic is flawed Why didn't they walk when they found that out in December?
Are you saying all treatments are worthless that fail to meet their primary end point? And therefore primary end points are never incorrectly selected?
Pretty clear on this had they selected 20% mortality reduction they probably would have made it.
- Forums
- ASX - By Stock
- MSB
- Disclosure issues
Disclosure issues, page-42
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.06 |
Change
0.030(2.91%) |
Mkt cap ! $1.210B |
Open | High | Low | Value | Volume |
$1.05 | $1.09 | $1.03 | $5.796M | 5.430M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 15990 | $1.06 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.08 | 48632 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 385 | 1.110 |
1 | 499 | 1.100 |
3 | 1410 | 1.065 |
4 | 46920 | 1.060 |
2 | 5771 | 1.050 |
Price($) | Vol. | No. |
---|---|---|
1.010 | 5000 | 1 |
1.060 | 11223 | 2 |
1.075 | 18282 | 1 |
1.080 | 71785 | 3 |
1.085 | 94467 | 6 |
Last trade - 16.10pm 02/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |